Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics (CYTOF)
OTHER OTC:CYTOF
RESEARCH TOOLSreports
CYTOF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.05 - $1.53
Previous CloseN/A
Volume627.00
Average Volume (3M)8.53K
Market Cap
$599.55K
Enterprise ValueN/A
Total Cash (Recent Filing)$49.57K
Total Debt (Recent Filing)CHF3.47M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Sep 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding5,715,472
10 Day Avg. Volume7,199
30 Day Avg. Volume8,534
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Altamira Therapeutics News
PremiumCompany Announcements
Altamira Therapeutics Announces AGM Results and Board Elections
PremiumCompany Announcements
Altamira Therapeutics Announces June 2025 Annual General Meeting
PremiumCompany Announcements
Altamira Therapeutics Reports 2024 Financial Progress
PremiumCompany Announcements
Altamira Therapeutics Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Altamira Therapeutics Announces RNA Delivery Progress and Financial Results
PremiumCompany Announcements
Altamira Therapeutics Amends Revenue Sharing Agreement with Altamira MedicaOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
CYTOF FAQ
What was Altamira Therapeutics’s price range in the past 12 months?
Altamira Therapeutics lowest stock price was $0.05 and its highest was $1.53 in the past 12 months.
What is Altamira Therapeutics’s market cap?
Altamira Therapeutics’s market cap is $599.55K.
When is Altamira Therapeutics’s upcoming earnings report date?
Altamira Therapeutics’s upcoming earnings report date is Sep 03, 2025 which is in 77 days.
How were Altamira Therapeutics’s earnings last quarter?
Altamira Therapeutics released its earnings results on Apr 30, 2025. The company reported -$0.883 earnings per share for the quarter, missing the consensus estimate of -$0.584 by -$0.299.
Is Altamira Therapeutics overvalued?
According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued.
Does Altamira Therapeutics pay dividends?
Altamira Therapeutics does not currently pay dividends.
What is Altamira Therapeutics’s EPS estimate?
Altamira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Altamira Therapeutics have?
Altamira Therapeutics has 5,715,472 shares outstanding.
What happened to Altamira Therapeutics’s price movement after its last earnings report?
Altamira Therapeutics reported an EPS of -$0.883 in its last earnings report, missing expectations of -$0.584. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of Altamira Therapeutics?
Currently, no hedge funds are holding shares in CYTOF
Company Description
Altamira Therapeutics
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
CYTOF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.Read More>Technical Analysis
Biodexa Pharmaceuticals
―
Applied DNA Sciences
―
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
Petros Pharmaceuticals
―